Obesity and Diabetes
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Published in Obesity and Diabetes Week, March 23rd, 2009
InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes (T2DM). INT131-007 is a 24 week, high dose active comparator (45mg Actos(R)) and placebo controlled study of INT131 at four doses in poorly controlled Type 2 diabetics.
"INT131-007 is an important study designed specifically to extend the encouraging findings from our Phase 2a study and demonstrate the unique properties of INT131, a potent insulin sensitizer, in patients with...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Cedars-Sinai Medical Center
Older patients with 1 type of heart failure may receive little or no benefit from drugs - Georgia State University
Reducing suicidal behaviors among adolescents - The Peninsula College of Medicine and Dentistry
New study of human pancreases links virus to cause of type 1 diabetes - Diabetes
New diabetes study findings have been reported from M.M.J. Nielen et al - Diabetes
Researchers from University of Melbourne publish new studies and findings in the area of diabetes - Life Sciences
Research on life sciences discussed by scientists at University of Milan - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
